Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIO: Olaparib vs Chemotherapy in Relapsed Ovarian Cancer
NCT02822157Phase 2Unknown
- Sponsor
- UZ Leuven
- Start
- Aug 2016
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in ovarian epithelial cancer, sponsored by UZ Leuven. Status: unknown.
02
Drugs
olaparib
03
Conditions
ovarian epithelial cancer
Beyond the preview
Go deeper on NCT02822157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02822157.